Adopting AI in RWD studies is the latest trend in the RWD industry. AI integrated RWD studies can enhance data anomaly detection, standardization, and quality check at the pre-processing stage. AI-powered RWD studies can serve as a valuable tool in collecting, organizing, and analysing the increasing amount of data generated from disparate datasets. AI integrated wearable devices/sensors can automatically and continuously collect patient data, relieving the patient of this task. Together with wearable technology, AI techniques offer new approaches to developing real-time, power-efficient, mobile, and personalized patient data.
The global RWD market is segmented based on Source (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Genomics Data, and Other Datasets), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post-market Surveillance, Medical Device Development & Approvals, and Other Applications), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography. The study also evaluates industry competitors and analyses their market share at the global and regional levels.
Download Free PDF Sample Copy of the Report (with COVID-19 Impact Analysis): https://www.meticulousresearch.com/download-sample-report/cp_id=5297
Scope of the Report
RWD Market, by Source
EMR/EHR/Clinical Data
Claims & Billing Data
Pharmacy Data
Product/Disease Registries Data
Genomics Data
Other Datasets
(Note Other Datasets segment includes data generated from mobile devices, wearable devices, and social media)
RWD Market, by Application
Market Access & Reimbursement/Coverage Decisions
Drug Development & Approvals
o Oncology
o Neurology
o Immunology
o Cardiovascular Diseases
o Other Therapeutic Areas
Post-market Surveillance
Medical Device Development & Approvals
Regulatory and Clinical Decision-Making
(Note Other Therapeutic Areas majorly include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)
RWD Market, by End User
Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users
(Note Other end users majorly include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)
RWD Market, by Geography
North America
o U.S.
o Canada
Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe (RoE)
Asia-Pacific (APAC)
o Japan
o China
o India
o South Korea
o Taiwan
o Singapore
o Rest of APAC (RoAPAC)
Latin America
Middle East & Africa
To gain more insights into the market with a detailed table of content and figures, click here : https://www.meticulousresearch.com/product/real-world-data-market-5297
Based on source, in 2022, the EMR/EHR/clinical data segment is estimated to account for the largest market share of the RWD market owing to the significant amounts of data generated in hospitals, the increasing adoption of EHR/EMR in hospitals, and the increased use of clinical data for RWE generation. EHRs are the commonly used form of healthcare database. EHR data is vital in collecting and generating actionable information at the FDA. The federal agency is focused on making real-world data (RWD) available for clinical studies as a strategic priority and intends to issue guidance on supporting more accessible clinical trials through a decentralized approach. Such initiatives would propel the adoption of EHR data for real-world data generation during the forecast period.
Based on application, in 2022, the market access & reimbursement/coverage decisions segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is primarily attributed to the increasing demand for real-world data to accelerate drug discovery & development and deliver a value-based price. With rising therapy costs, healthcare payers are focusing on evidence of clinical value for making decisions associated with providing coverage. RWD helps and provides a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. The pharmaceutical, biotech, and medical device manufacturers use RWD derived from patient populations to analyse the clinical trial data to deliver a value-based price that appeals to more payers with increased value and provides maximum profit to the company. Payers use RWD to understand how treatments work and guide their medication coverage and reimbursement decisions.
Based on end user, in 2022, the pharmaceutical, biotechnology, and medical device companies segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is attributed to the increasing importance of RWD in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape is developing and is shifting from volume to value-based care. Pharmaceutical companies have been looking for new ways to provide the best treatments to patients. RWD helps in understanding real-life clinical practices and actual health outcomes of drugs. Pharmaceuticals and biotechnology companies have adopted various strategies to demonstrate the value of their products, faster data collection, drive drug development, address regulatory requirements, support outcomes-based contracts, minimize the risk of product failure, and reduce products time to reach the market.
Request Customization Report : https://www.meticulousresearch.com/request-customization/cp_id=5297
Geographic Review:
This market research report analyses major geographies and provides a comprehensive analysis of North America (U.S., Canada), Asia-Pacific (China, Japan, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.
Key Players
Key companies operating in the global RWD market are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).
You can Buy Report from Here : https://www.meticulousresearch.com/Checkout/62327099
Key questions answered in the report-
Which are the high-growth market segments in terms of source, application, end user, and regions/countries?
What was the historical market for real-world data (RWD) market across the globe?
What are the market forecasts and estimates for the period 20222029?
What are the major drivers, restraints, challenges, opportunities, and trends in the global real-world data (RWD) market?
Who are the major players in the global real-world data (RWD) market?
How is the competitive landscape, and who are the market leaders in the global real-world data (RWD) market?
What are the recent developments in the real-world data (RWD) market?
What are the different strategies adopted by the major players in the real-world data (RWD) market?
What are the geographical trends and high growth regions/countries?
